Lyra Direct SARS-CoV-2 Assay Instructions Revised for False Negative Risk
The Lyra Direct SARS-CoV-2 assay can produce false negatives on certain PCR machines when specimens have high viral loads. Revised instructions address this diagnostic failure risk affecting approximately 81,910 kits distributed worldwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II device with documented false negative risk affecting COVID-19 diagnostic accuracy. Source text does not report illnesses or injuries, qualifying as a risk-of-harm product where injury has not yet been reported per rubric score 3.
Plain-English summary
The Lyra Direct SARS-CoV-2 Assay is a real-time RT-PCR diagnostic test manufactured by Quidel Corporation for detecting COVID-19 in patients with suspected infection. The FDA has identified a potential failure mode affecting the test's performance.
Under specific conditions, nasal, nasopharyngeal, or oropharyngeal specimens from patients with high SARS-CoV-2 viral loads may be falsely interpreted as negative when using certain laboratory equipment. The failure occurs when target amplification happens before a cycle-threshold value of 5. Affected equipment includes the Thermo Fisher QuantStudio 7 Pro, Applied Biosystems 7500 Fast Dx, Applied Biosystems 7500, Bio-Rad CFX96 Touch, Roche LightCycler LC 480 II/cobas z 480, and Qiagen Rotor-Gene MDx. Approximately 81,910 kits from all lot numbers have been distributed worldwide to the United States, Puerto Rico, Canada, Panama, Virgin Islands, Germany, and Honduras.
Quidel Corporation has issued revised Instructions for Use to address this issue. Laboratories using this assay on the affected equipment models should consult the updated guidance.
The recalled product
- Product
- Lyra Direct SARS-CoV-2 Assay Emergency Use Authorization- Ref: M124. The Lyra Direct SARS-CoV-2 Assay is a real-time RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal (NS), nasopharyngeal (NP), or oropharyngeal (OP) direct swab speci
- Manufacturer
- Quidel Corporation
- Hazard
- Affected units
- 81,910
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots
Distribution
Related recalls
Same manufacturer · Quidel Corporation
See all →- HighQuickVue Dipstick Strep A Test Recalled for False Positive Results
FDA (Devices) · 2026-05-20
- HighDipstick strep A tests recalled over potential for false positive results
FDA (Devices) · 2025-09-17
- HighMedical diagnostic test kits recalled due to misaligned results window
FDA (Devices) · 2024-05-01
- HighQuidel InflammaDry MMP-9 Test: Misaligned Results Window May Cause False Negatives
FDA (Devices) · 2024-05-01
- ModerateQuidel Sofia 2 Flu + SARS Test Kits Recalled for Incorrect Expiration Dates
FDA (Devices) · 2024-02-21
Same hazard · false negative
See all →- HighHealthmark ProChek-II Medical Tests Recalled for Expired Ingredient
FDA (Devices) · 2026-09-02
- HighSiemens Immulite 2000 Syphilis Screen Recall for Negative Bias
FDA (Devices) · 2026-08-26
- HighSiemens Immulite 2000 Syphilis Screen Recalled for Negative Bias
FDA (Devices) · 2026-08-26
- HighHologic Aptima HPV assay may produce invalid or false negative results
FDA (Devices) · 2026-03-25
- HighHeparin antibody test kits recalled over a defect producing negative results
FDA (Drugs) · 2026-01-21